Literature DB >> 21389144

Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis--effects of pancreatic enzyme supplementation.

Paul Kuo1, Julie E Stevens, Antonietta Russo, Anne Maddox, Judith M Wishart, Karen L Jones, Hugh Greville, David Hetzel, Ian Chapman, Michael Horowitz, Christopher K Rayner.   

Abstract

CONTEXT: Postprandial hyperglycemia is an important clinical problem in cystic fibrosis (CF), but the contribution of fat malabsorption, rapid gastric emptying, and the incretin axis has not been widely considered.
OBJECTIVE: The aim of this study was to evaluate these aspects of gut function in nondiabetic CF patients. DESIGN AND
SETTING: We conducted a randomized, double-blind, placebo-controlled crossover study at a clinical research laboratory. PATIENTS: Five nondiabetic CF patients (three males; age, 25.8 ± 1.0 yr; body mass index, 20.2 ± 1.1 kg/m(2)) with exocrine pancreatic insufficiency and six healthy subjects of similar age and body mass index participated in the study.
INTERVENTIONS: CF patients consumed a radiolabeled mashed potato meal on 2 separate days, together with four capsules of Creon Forte (100,000 IU lipase) or placebo. Healthy subjects consumed the meal once, without pancreatic enzymes. MAIN OUTCOME MEASURES: Gastric emptying was measured using scintigraphy, and blood was sampled frequently for blood glucose and plasma glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon concentrations.
RESULTS: CF patients had more rapid gastric emptying (P < 0.001), impaired secretion of GLP-1 (P < 0.01) and GIP (P < 0.001), and greater postprandial glycemic excursions (P < 0.001) than healthy subjects. Pancreatic enzyme supplementation normalized gastric emptying and GLP-1 secretion and tended to increase glucagon (P = 0.08), but did not completely restore GIP secretion or normalize postprandial blood glucose. There was an excellent correlation between gastric emptying and blood glucose concentration at 60 min (R = 0.75; P = 0.01).
CONCLUSIONS: Pancreatic enzyme supplementation plays an important role in incretin secretion, gastric emptying, and postprandial hyperglycemia in CF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389144     DOI: 10.1210/jc.2010-2460

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 2.  Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

Authors:  Phil A Hart; Melena D Bellin; Dana K Andersen; David Bradley; Zobeida Cruz-Monserrate; Christopher E Forsmark; Mark O Goodarzi; Aida Habtezion; Murray Korc; Yogish C Kudva; Stephen J Pandol; Dhiraj Yadav; Suresh T Chari
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-10-12

3.  Incretin dysfunction and hyperglycemia in cystic fibrosis: Role of acyl-ghrelin.

Authors:  Xingshen Sun; Yaling Yi; Bo Liang; Yu Yang; Nan He; Katie Larson Ode; Aliye Uc; Kai Wang; Katherine N Gibson-Corley; John F Engelhardt; Andrew W Norris
Journal:  J Cyst Fibros       Date:  2019-02-07       Impact factor: 5.482

4.  Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets.

Authors:  Alicia K Olivier; Yaling Yi; Xingshen Sun; Hongshu Sui; Bo Liang; Shanming Hu; Weiliang Xie; John T Fisher; Nicholas W Keiser; Diana Lei; Weihong Zhou; Ziying Yan; Guiying Li; Turan I A Evans; David K Meyerholz; Kai Wang; Zoe A Stewart; Andrew W Norris; John F Engelhardt
Journal:  J Clin Invest       Date:  2012-09-17       Impact factor: 14.808

Review 5.  Diagnosis and treatment of diabetes mellitus in chronic pancreatitis.

Authors:  Nils Ewald; Philip D Hardt
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

6.  Effect of Sitagliptin on Islet Function in Pancreatic Insufficient Cystic Fibrosis With Abnormal Glucose Tolerance.

Authors:  Andrea Kelly; Saba Sheikh; Darko Stefanovski; Amy J Peleckis; Sarah C Nyirjesy; Jack N Eiel; Aniket Sidhaye; Russell Localio; Robert Gallop; Diva D De Leon; Denis Hadjiliadis; Ronald C Rubenstein; Michael R Rickels
Journal:  J Clin Endocrinol Metab       Date:  2021-05-22       Impact factor: 5.958

7.  Effects of GLP-1 and GIP on Islet Function in Glucose-Intolerant, Pancreatic-Insufficient Cystic Fibrosis.

Authors:  Sarah C Nyirjesy; Amy J Peleckis; Jack N Eiel; Kathryn Gallagher; Andriana Doliba; Abigail Tami; Anneliese J Flatt; Diva D De Leon; Denis Hadjiliadis; Saba Sheikh; Darko Stefanovski; Robert Gallop; David A D'Alessio; Ronald C Rubenstein; Andrea Kelly; Michael R Rickels
Journal:  Diabetes       Date:  2022-10-01       Impact factor: 9.337

8.  Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor.

Authors:  Angel Li; Tim Vigers; Laura Pyle; Edith Zemanick; Kristen Nadeau; Scott D Sagel; Christine L Chan
Journal:  J Cyst Fibros       Date:  2018-08-10       Impact factor: 5.482

Review 9.  Relationships between gastric emptying, postprandial glycemia, and incretin hormones.

Authors:  Chinmay S Marathe; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Diabetes Care       Date:  2013-05       Impact factor: 19.112

10.  Pancreatic enzyme replacement therapy for people with cystic fibrosis.

Authors:  Usha Rani R Somaraju; Arturo Solis-Moya
Journal:  Cochrane Database Syst Rev       Date:  2020-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.